C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation [PDF]
, 2015 Complement C1q is the activator of the classical pathway. However, it is now recognized that C1q can exert functions unrelated to complement activation.
Agostinis, C +9 more
core +3 more sources
Bispecific Antibodies Against HIV [PDF]
Cell, 2016 Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire +2 more sources
Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration
Advanced Healthcare Materials, EarlyView.Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu +4 more
wiley +1 more source
Bispecific antibodies in cancer immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy, 2018 Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and ...
Eva Dahlén +2 more
doaj +1 more source
Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds
Antibodies, 2018 Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs).
Lilach Vaks +9 more
doaj +1 more source
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Life, 2021 Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen +2 more
doaj +1 more source
Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis [PDF]
, 2009 Peritoneal carcinomatosis (PC) from epithelial tumors is a fatal diagnosis without efficient treatment. Trifunctional antibodies (trAb) are novel therapeutic approaches leading to a concerted anti-tumor activity resulting in tumor cell destruction.
Michael A Ströhlein +37 more
core +3 more sources
Advanced Science, EarlyView.A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
EXTH-08. REPLACEMENT OF MICROGLIA BY BRAIN-ENGRAFTED MACROPHAGES PREVENTS MEMORY DEFICITS AFTER THERAPEUTIC WHOLE-BRAIN IRRADIATION [PDF]
, 2019 Microglia have a distinct origin compared to blood circulating myeloid cells. Under normal physiological conditions, microglia are maintained by self-renewal, independent of hematopoietic progenitors. Following genetic or pharmacologic depletion, newborn
Boosalis, Zoe +6 more
core +1 more source
Bispecific Antibody-Functionalized Upconversion Nanoprobe [PDF]
Analytical Chemistry, 2018 Upconversion nanoparticles (UCNPs) are new optical probes for biological applications. For specific biomolecular recognition to be realized for diagnosis and imaging, the key lies in developing a stable and easy-to-use bioconjugation method for antibody modification.
Hao He +7 more
openaire +3 more sources